E2F Decoy Oligonucleotide for Genetic Engineering of Vascular Bypass Grafts
- 1 April 1998
- journal article
- review article
- Published by Mary Ann Liebert Inc in Antisense and Nucleic Acid Drug Development
- Vol. 8 (2) , 171-176
- https://doi.org/10.1089/oli.1.1998.8.171
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts.Journal of Clinical Investigation, 1997
- The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expressionJournal of Vascular Surgery, 1995
- The retinoblastoma protein and cell cycle controlCell, 1995
- Principles of CDK regulationNature, 1995
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Retinoblastoma protein switches the E2F site from positive to negative elementNature, 1992
- Stranger in a strange land: The pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteriesProgress in Cardiovascular Diseases, 1991
- Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia[mdash ]A reviewJournal of Vascular Surgery, 1991
- G 1 Events and Regulation of Cell ProliferationScience, 1989
- Kinetics of vein graft hyperplasia: Association with tangential stressJournal of Vascular Surgery, 1987